Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CCR1 | P32246 | 3/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
| ▸ | CCR8 | P51685 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10627854 | 0.87 | LMNA (0.34) | LMNACCR1CCR5CCR8CYP3A4 | |
| Propionic Acid SCHEMBL28455719 | 0.87 | ALDH1A1 (0.37) | LMNACCR1CCR5CCR8CYP3A4 | |
| Phthalimide SCHEMBL8558624 | 0.84 | GSK3B (0.40) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL11497898 | 0.79 | MAP4K4 (0.33) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL1980670 | 0.77 | LMNA (0.58) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL528130 | 0.76 | LMNA (0.40) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL8669721 | 0.76 | KDM4E (0.40) | LMNACYP3A4KDM4EHSP90AA1MAPT | |
| SCHEMBL21001801 | 0.74 | LMNA (0.61) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL157930 | 0.74 | LMNA (0.61) | LMNACCR1CCR5CCR8CYP3A4 | |
| SCHEMBL31143538 | 0.73 | LMNA (0.59) | LMNACCR1CCR5CCR8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2025-03-06 | — | — | US | claimed |
| EP-4463153-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | Eleusis Therapeutics US, Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2023-09-07 | — | — | US | claimed |
| WO-2023137094-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. (US) | 2023-07-20 | — | — | WO | claimed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| EP-4178569-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | Eleusis Therapeutics US, Inc. (US) | 2023-05-17 | — | — | EP | claimed |
| WO-2022082058-A1 | METHOD OF TREATMENT BY TRYPTAMINE ALKALOIDS | ELEUSIS THERAPEUTICS US, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022011350-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | ELEUSIS THERAPEUTICS US, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| US-11154537-B2 | Method of treatment for ketamine infusion | ELEUSIS THERAPEUTICS US, INC. (US) | 2021-10-26 | — | — | US | claimed |
| EP-0395527-B1 | Imidazobenzodiazepines and their salts, process for preparation, use as medicaments, and compositions containing these compounds | ROUSSEL UCLAF (FR) | 1994-09-14 | — | — | EP | claimed |
| EP-0305298-B1 | IMIDAZOBENZODIAZEPINES AND THEIR ACID ADDITION SALTS, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-09-22 | — | — | EP | claimed |
| EP-0433163-A2 | Process for the preparation of imidazobenzodiazepines and their salts | ROUSSEL-UCLAF (FR) | 1991-06-19 | — | — | EP | claimed |
| EP-0423032-A2 | Process for the preparation of isoxazolyl and isothiazolyl imidazobenzodiazepines, new derivatives thus obtained, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1991-04-17 | — | — | EP | claimed |
| EP-0395527-A1 | Imidazobenzodiazepines and their salts, process for preparation, use as medicaments, and compositions containing these compounds | ROUSSEL-UCLAF (FR) | 1990-10-31 | — | — | EP | claimed |
| EP-0305298-A2 | Imidazobenzodiazepines and their acid addition salts, process and intermediates for their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1989-03-01 | — | — | EP | claimed |
| US-4670433-A | CARDIOVASCULAR DISORDERS | A/S FERROSAN (DK) | 1987-06-02 | — | — | US | claimed |
| EP-0100906-B1 | TRI- AND TETRACYCLIC IMIDAZO(1,5-A)(1,4)BENZODIAZEPIN-1-CARBOXYLIC-ACID DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-05-13 | — | — | EP | claimed |
| EP-0197282-A1 | Novel oxadiazolyl imidazobenzodiazepine derivatives and methods of preparing such compounds | A/S FERROSAN (DK) | 1986-10-15 | — | — | EP | claimed |
| EP-0100906-A2 | Tri- and tetracyclic imidazo(1,5-a)(1,4)benzodiazepin-1-carboxylic-acid derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154537-B2 | Method of treatment for ketamine infusion | KCND2, KCND3, KCNH3 | LMNA 967/4885CCR1 3000/4885CCR5 2243/4885 |
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | SRI, PROC, PRDX6 | LMNA 1259/4885CCR1 4471/4885CCR5 3200/4885 |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | PNN, HTR1B, GABBR1 | LMNA 506/4885CCR1 1939/4885CCR5 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.